Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug



A third member of a key FDA panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, CNBC has learned.



Source link

Comments